CG Invites Co., Ltd.
Financials
Valuation Metrics
CG Invites Co., Ltd.'s Market Cap is ₩658B. At end of 2025 it was ₩1143B. Ranked #1539 of 2,410 in KR market (top 64%), #897 of 1,631 on KOSDAQ (top 55%), #169 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 73%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 65.82B KRW | KR#1,539/2,410 Sec#169/231 |
| Revenue | 27.03B KRW | KR#2,062/2,410 Sec#144/231 |
| Net Income | -8.75B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 220.05B KRW | KR#1,248/2,410 Sec#91/231 |
| Net Assets | 105.33B KRW | KR#1,376/2,410 Sec#107/231 |
| Employees | 80 | KR#1,806/2,410 Sec#152/231 |
| Value | ||
| P/B | 0.62x | KR#1,077/2,410 Sec#58/231 |
| P/S | 2.43x | KR#1,933/2,410 Sec#114/231 |
| FCF Yield | -30.51% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -8.31% | KR#1,896/2,410 Sec#139/231 |
| ROA | -3.98% | KR#1,880/2,410 Sec#134/231 |
| Op. Margin | -83.80% | KR#2,278/2,410 Sec#170/231 |
| Revenue Growth | 98.44% | KR#88/2,410 Sec#18/231 |
| Financial Health | ||
| Debt Ratio | 108.93% | KR#1,621/2,410 Sec#186/231 |
| Total Debt | 43.59B KRW | KR#1,052/2,410 Sec#73/231 |
| FCF | -20.08B KRW | KR#1,888/2,410 Sec#180/231 |
| Cash | 5.94B KRW | KR#1,943/2,410 Sec#175/231 |
| Current Ratio | 0.34x | KR#2,190/2,410 Sec#213/231 |
| Performance | ||
| 1Y Return | -42.82% | KR#1,857/2,410 Sec#164/231 |
| 1M Return | -7.96% | KR#1,298/2,410 Sec#133/231 |
| From 52W High | -48.65% | KR#1,144/2,410 Sec#91/231 |
| 1Y MDD | -54.55% | KR#1,161/2,410 Sec#96/231 |
| Trading | ||
| Volume | 38,496 shares | KR#680/2,410 Sec#71/231 |
| Trading Value | 32.8M KRW | KR#1,585/2,410 Sec#167/231 |
| Foreign Own. | 2.29% | KR#1,527/2,410 Sec#144/231 |
| Per Share | ||
| EPS | -114 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,370 KRW | KR#2,224/2,410 Sec#196/231 |
Company Info
CG Invites, established in 2000, changed its name in 2023 and was listed on KOSDAQ in 2006. The bio company specializes in digital genome new drug development, Printed Circuit Board/hot pack manufacturing, and healthcare solutions. It commercialized the anti-inflammatory analgesic 'Acellex' as South Korea's first new drug and is conducting US FDA clinical trials for molecular targeted anti-cancer drugs. CG Invites is establishing a healthcare platform that merges genome analysis with artificial intelligence and big data, aiming to become a leading company in the genome industry. The company is headquartered in Gangseo-gu, Seoul.